Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV‐1 infected patients failing HAART

The extent to which HIV‐1 proviral DNA mutations cause clinically relevant antiretroviral resistance is still controversial. Paired plasma HIV‐1 RNA and whole blood DNA were compared in patients failing HAART to investigate if the additional knowledge of archived mutations could improve the selection of potentially active drugs. Seventy‐three HIV‐1‐infected patients with first/second HAART failure were studied before starting a new regimen based on RNA genotyping. Follow‐up data after a 12‐week therapy were available. DNA genotyping was retrospectively performed on stored whole blood samples and mutational profiles were compared to those from RNA. The mean number of IAS pol mutations was significantly higher in RNA (4.45 ± 2.76) than in DNA (2.88 ± 2.47) (P < 0.001). DNA genotyping provided a 6% increase in detection of resistance‐associated mutations. Among 64/73 patients showing discordant DNA/RNA profiles, 54 (84%) also differed for predicted active drugs. 16/73 (22%) patients had ≥1 mutation revealed by DNA genotyping alone, probably affecting therapy success in 2/16. However, neither RNA/DNA discordance nor detection of isolated DNA mutations were statistically associated with outcome. In conclusion, plasma RNA remains the elective choice for HIV genotyping in patients with therapy failure, even if the detection of proviral resistance‐associated mutations, not simultaneously found in RNA, is a frequent event. Therefore, in some cases DNA plus RNA genotyping might assist in choosing more accurately subsequent antiretroviral regimens. J. Med. Virol. 80:1695–1706, 2008. © 2008 Wiley‐Liss, Inc.

[1]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[2]  S. Luchters,et al.  Feasibility of Detecting Human Immunodeficiency Virus Type 1 Drug Resistance in DNA Extracted from Whole Blood or Dried Blood Spots , 2007, Journal of Clinical Microbiology.

[3]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: 2007. , 2007, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[4]  M. Zazzi,et al.  Use of peripheral blood DNA for genotype antiretroviral resistance testing in drug-naive HIV-infected subjects. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  A. Geretti,et al.  Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. , 2007, The Journal of antimicrobial chemotherapy.

[6]  M. Zazzi,et al.  Both Human Immunodeficiency Virus Cellular DNA Sequencing and Plasma RNA Sequencing Are Useful for Detection of Drug Resistance Mutations in Blood Samples from Antiretroviral-Drug-Naive Patients , 2007, Journal of Clinical Microbiology.

[7]  C. Scagnolari,et al.  Genotypic Resistance of Archived and Circulating Viral Strains in the Blood of Treated HIV-Infected Individuals , 2007, Journal of acquired immune deficiency syndromes.

[8]  M. Re,et al.  Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. , 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[9]  N. Saksena,et al.  Drug resistance and viral evolution in plasma and peripheral blood cells during structured treatment interruption (STI) and non-interrupted HAART. , 2007, Current HIV research.

[10]  Paul Sandstrom,et al.  HIV-1 drug resistance surveillance using dried whole blood spots , 2007, Antiviral therapy.

[11]  W. Heneine,et al.  Evaluation of Dried Blood Spots for Human Immunodeficiency Virus Type 1 Drug Resistance Testing , 2006, Journal of Clinical Microbiology.

[12]  A. Lazzarin,et al.  Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  G. Angarano,et al.  HIV infection and protease genetic diversity in a rural area of the Southern Central African Republic , 2005, Journal of medical virology.

[14]  Klaus Korn,et al.  Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. , 2005, The Journal of infectious diseases.

[15]  N. Saksena,et al.  Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[16]  P. Narciso,et al.  Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients , 2005, AIDS.

[17]  JD Lundgren,et al.  Updated European Recommendations for the Clinical Use of HIV Drug Resistance Testing , 2004, Antiviral therapy.

[18]  S. Oka,et al.  Emergence of Protease Inhibitor Resistance–Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year , 2003, Journal of acquired immune deficiency syndromes.

[19]  J. R. Fiore,et al.  Mutational patterns of paired blood and rectal biopsies in HIV‐infected patients on HAART , 2003, Journal of medical virology.

[20]  G. d’Ettorre,et al.  Drug-Associated Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells of Human Immunodeficiency Virus Type 1-Infected Patients for Whom Highly Active Antiretroviral Therapy Is Failing , 2003, Journal of Clinical Microbiology.

[21]  N. Saksena,et al.  Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. , 2003, Virology.

[22]  P. Keiser,et al.  Role of Sequencing in Therapy Selection , 2002, Journal of acquired immune deficiency syndromes.

[23]  F. Baldanti,et al.  Analysis of HIV drug‐resistant quasispecies in plasma, peripheral blood mononuclear cells and viral isolates from treatment‐naive and HAART patients , 2001, Journal of medical virology.

[24]  M. Zazzi,et al.  Divergent Distribution of HIV-1 Drug-Resistant Variants on and off Antiretroviral Therapy , 2001, Antiviral therapy.

[25]  N. Saksena,et al.  Molecular evidence for drug-induced compartmentalization of HIV-1 quasispecies in a patient with periodic changes to HAART , 2000, AIDS.

[26]  C. Sabin,et al.  Substantial correlation between HIV type 1 drug-associated resistance mutations in plasma and peripheral blood mononuclear cells in treatment-experienced patients. , 2000, AIDS research and human retroviruses.

[27]  J. Lisziewicz,et al.  Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy , 1999, Nature Medicine.

[28]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[29]  R Brookmeyer,et al.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. , 1997, Science.

[30]  C. Loveday,et al.  The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. , 1995, AIDS research and human retroviruses.